President of the Spanish Society of Immunology (SEI) and former secretary of the Spanish Society of Transplantation (SET)
Toledo and Alicante are suffering the first outbreaks of measles recorded in Spain since the pandemic, El País reported today. In total, 15 cases have been confirmed since 1 January, of which seven are imported and eight autochthonous.
A study has analysed more than 100 environmental factors and their impact on the immune response. After studying about a thousand volunteers, its conclusions are that smoking is the factor that causes the most alterations in defences. While some changes are transient, others may remain for years after quitting. The results are published in the journal Nature.
Currently, when an organ transplant is performed, the patient has to take immunosuppressive drugs to prevent his or her system from rejecting the new organ. These drugs must be taken for life and have numerous side effects. In a phase 1 clinical trial, researchers gave patients receiving a liver transplant regulatory dendritic cells derived from the original donor, with the hypothesis that these cells could 'teach' the recipient's immune system to tolerate the new organ. The research, published in Science Translational Medicine, suggests that this treatment could reduce or even eliminate the need for long-term use of immunosuppressants.
The European Medicines Agency (EMA) has licensed Hipra's vaccine - currently called Bimervax - against SARS-CoV-2 as a booster in people aged 16 years and older who have previously been vaccinated with mRNA vaccines. The EMA began the ongoing evaluation of the vaccine, which was expected to be approved in the middle of last year, on 29 March 2022.
To estimate the effectiveness of two or three doses of vaccines against covid-19 infection and hospitalisation, researchers in Denmark conducted a study of all previously uninfected Danish residents aged 12 years and older. The conclusion of the research, which is published in PLOS Medicine, is that a third dose provided greater protection against infection and hospitalisation with omicron than two vaccines.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved an updated version of the covid-19 vaccine manufactured by Moderna that also targets the omicron variant. It is intended to serve as a booster dose for adults.
Two studies published in The Lancet Infectious Diseases confirm that covid-19 vaccines offer additional protection for those already infected with SARS-CoV-2, especially against severe disease.
The director of the Vaccine Strategy of the European Medicines Agency (EMA), Marco Cavaleri, told a press conference on 11 January that "it is not sustainable in the long term to continue giving booster doses every three or four months [to the general population]". Spanish immunologists agree that this is not the right thing to do. In these reactions they explain why.
In the last few days, data, preprints, press releases and even graphs have started to arrive via social media showing how neutralising antibodies against the omicron variant behave. These studies are preliminary and we will have to wait and see how these lab data translate into the real world.
The European Medicines Agency issued its recommendations yesterday afternoon regarding the administration of a third dose of the Comirnaty (Pfizer/BioNTech) and Spikevax (Moderna) vaccines. These are the reactions of several experts on the matter.